Furthermore, we pioneered synergy screening with established drugs such as cytarabine, doxorubicin, etoposide, and SNS-032, which revealed that HDAC6 inhibition combined with chemotherapeutic drugs can deliver a synergistic benefit in γδ T-NHL or NKTCL. The gene discussed is HDAC6; the disease is non-Hodgkin lymphoma.